BTK and COVID-19: Indeed, during the COVID‐19 pandemic, BTK has been shown to be activated in monocytes and intervention with the BTK inhibitor acalabrutinib has been reported to reduce systemic inflammation in patients with severe COVID‐19 (Roschewski et al., 2020).